Corpus Intelligence IC Memo — PROVIDENCE HOLY CROSS MED. CENTER 2026-04-26 09:36 UTC
IC Memo — PROVIDENCE HOLY CROSS MED. CENTER
Investment Committee Memorandum | CA | 286 beds | Grade C | EBITDA uplift $40.9M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

PROVIDENCE HOLY CROSS MED. CENTER

CCN 050278 | LOS ANGELES, CA | 286 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

PROVIDENCE HOLY CROSS MED. CENTER is a 286-bed community hospital in LOS ANGELES, CA with $555.8M in net patient revenue and a -13.6% operating margin. The hospital serves a payer mix of 18.6% Medicare, 0.0% Medicaid, and 81.4% commercial.

Thesis: Undervalued. Our ML models identify $40.9M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -13.6% to -6.2% (+736bps).

Net Revenue HCRIS$555.8M
Current EBITDA COMPUTED$-75.4M
Operating Margin COMPUTED-13.6%
Occupancy HCRIS77.4%
Revenue / Bed COMPUTED$1.9M
Net-to-Gross HCRIS20.1%
Distress Probability MLnan%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
183
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -13.6% places it below the state median. Among 183 size-comparable peers (143-572 beds), the median margin is -3.9%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (143-572), prioritizing same-state peers. 183 hospitals in the comp set.

HospitalStateBedsRevenueMargin
PROVIDENCE HOLY CROSS MED. CEN (Target)CA286$555.8M-13.6%
RONALD REAGAN UCLACA446$2.62B-6.8%
LUCILE PACKARD CHILDRENS HOSPICA394$2.39B-0.8%
UCI MEDICAL CENTERCA397$1.90B-2.5%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%
RADY CHILDRENS HOSPITAL - SAN CA401$1.82B14.8%
HARBOR-UCLA MEDICAL CENTERCA369$1.54B-6.4%
HOAG MEMORIAL HOSPITAL PRESBYTCA512$1.37B-3.9%
SUTTER MEDICAL CENTER - SACRAMCA523$1.36B0.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $40.9M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$11.7M+210bp18mo
Cost to Collect4.5%2.5%$11.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$11.0M+198bp12mo
A/R Days Reduction5200.0%3800.0%$6.8M+122bp9mo
Clean Claim Rate88.0%96.0%$356K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$11.7M
Cost to Collect
$11.1M
Denial Rate Reduction
$11.0M
A/R Days Reduction
$6.8M
Clean Claim Rate
$356K
Total EBITDA Uplift$40.9M
Current EBITDA$-75.4M
+ RCM Uplift+$40.9M
Pro Forma EBITDA$-34.5M
Current Margin-13.6%
Pro Forma Margin-6.2%
WC Released (1x)$21.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-116.0M$-88.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-116.0M$-134.7M0.00x-100.0%
Bull Case9.0x11.0x$-104.4M$-37.4M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-104.4M$-71.6M0.00x-100.0%
Bear Case11.0x10.0x$-127.6M$-255.1M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-127.6M$-322.0M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 183 hospitals with 143-572 beds
  • Same-state prioritization (n=184)
  • Comp margins: P25=-15.6% / P50=-3.9% / P75=4.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.